NCT06123962 ALI/ARDS Clinical Sub-phenotyping Study
| NCT ID | NCT06123962 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China-Japan Friendship Hospital |
| Condition | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2023-12-14 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2023-12-14 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Construct a structured clinical data and biosample information platform for Chinese patients with acute lung injury/ acute respiratory distress syndrome. 2. By deciphering the heterogeneity of patients with acute lung injury/ acute respiratory distress syndrome, achieve clinical, longitudinal physiological, and biological sub-phenotyping to guide individualized precision treatment and improve prognosis.
Eligibility Criteria
Inclusion Criteria: * Meet the diagnostic criteria for Acute Respiratory Distress Syndrome (ARDS) according to the updated global definition in 2023. * The patient or their legal representative signs an informed consent form. Exclusion Criteria: * Individuals aged less than 18 years old. * Those who refuse to participate in the study.
Contact & Investigator
Jingen Xia
STUDY DIRECTOR
China-Japan Friendship Hospital
Frequently Asked Questions
Who can join the NCT06123962 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06123962 currently recruiting?
Yes, NCT06123962 is actively recruiting participants. Contact the research team at 13466396561@163.com for enrollment information.
Where is the NCT06123962 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06123962 clinical trial?
NCT06123962 is sponsored by China-Japan Friendship Hospital. The principal investigator is Jingen Xia at China-Japan Friendship Hospital. The trial plans to enroll 1,500 participants.